UPCNasdaqPharmaceutical PreparationsFiscal year ends September 30
Universe Pharmaceuticals INC
Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 20-F on Jan 29, 2026
$3.76−0.17 (-4.33%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Universe Pharmaceuticals statistics
Financials through Mar 31, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Universe Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $2.12M | $166.30M |
| Enterprise Value | -$19.55M | $88.19M |
| PS Ratio | 0.00 | 3.65 |
| PB Ratio | 0.04 | 2.03 |
| P/TBV Ratio | 0.04 | 2.29 |
Enterprise value
| Measure | Universe Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | -0.00 | 2.51 |
Income (trailing twelve months)
| Measure | Universe Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $17.86B | $58.34M |
| Gross Profit | $6.30B | $105.94M |
| Operating Income | -$2.92B | -$21.40M |
| Pretax Income | -$3.67B | -$14.34M |
| Net Income | -$3.67B | -$22.46M |
| EBITDA | -$2.40B | -$16.91M |
| EPS (Diluted) | -$8.06 | -$0.83 |
Margins
| Measure | Universe Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 35.3% | 52.9% |
| Operating Margin | -16.3% | -44.0% |
| Pretax Margin | -20.6% | -13.3% |
| Profit Margin | -20.6% | -40.2% |
| EBITDA Margin | -13.4% | -30.2% |
| FCF Margin | -29.8% | -9.27% |
Returns
| Measure | Universe Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -6626.5% | -53.2% |
| Return on Assets (ROA) | -5138.2% | -40.9% |
| Return on Invested Capital (ROIC) | -10999.2% | -32.4% |
| Return on Capital Employed (ROCE) | -5043.1% | -38.1% |
Growth
| Measure | Universe Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -22.4% | 5.96% |
| Revenue Growth (3Y CAGR) | 663.4% | 2.25% |
| Revenue Growth (5Y CAGR) | 257.2% | 6.48% |
Balance sheet
| Measure | Universe Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $29.05M | $61.43M |
| Total Debt | $7.38M | $118.52M |
| Net Cash (Debt) | $21.67M | $15.35M |
| Net Cash Per Share | $38.47 | $0.66 |
| Equity (Book Value) | $55.65M | $49.09M |
| Book Value Per Share | $98.78 | $1.37 |
| Tangible Book Value | $55.34M | $23.52M |
| Working Capital | $41.56M | $76.81M |
Financial position
| Measure | Universe Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 4.05 | 3.34 |
| Quick Ratio | 3.22 | 2.44 |
| Debt / Equity | 0.13 | 0.52 |
| Interest Coverage | -10.08 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Universe Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$5.05B | -$12.35M |
| Capital Expenditures | -$266.77M | -$1.08M |
| Free Cash Flow | -$5.32B | -$20.22M |
| FCF Per Share | -$9442.09 | -$0.42 |
Efficiency
| Measure | Universe Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 249.89 | 0.39 |
| Inventory Turnover | 5837.76 | 2.70 |
| Revenue Per Employee | $79.37M | $404.87K |
| Profits Per Employee | -$16.32M | -$703.34K |
| Employee Count | 225 | 74 |
Dividends and yields
| Measure | Universe Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -173361.0% | -23.3% |
| FCF Yield | -251120.0% | -8.72% |
| Buyback Yield | -708165.0% | -0.59% |
| Shareholder Yield | -708165.0% | 0.00% |
Shares
| Measure | Universe Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 563,338 | 58,127,000 |
| Shares Change (YoY) | 3174.9% | 10.9% |
Scores
| Measure | Universe Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | 115.72 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Universe Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.